Drugs

, Volume 74, Issue 3, pp 297–311

T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

  • Mahmoud H. Mosli
  • Jesus Rivera-Nieves
  • Brian G. Feagan
Review Article

DOI: 10.1007/s40265-013-0176-2

Cite this article as:
Mosli, M.H., Rivera-Nieves, J. & Feagan, B.G. Drugs (2014) 74: 297. doi:10.1007/s40265-013-0176-2

Abstract

The medical management of idiopathic inflammatory bowel disease (IBD) has historically been based upon the use of broad-spectrum anti-inflammatory drugs such as corticosteroids and thiopurines. Recently, the identification of novel mechanisms central to the pathophysiology of IBD has provided more specific targets, including inhibition of leukocyte trafficking to the gut. In this article, we discuss the molecular biology of intestinal leukocyte trafficking and review the emerging therapies that target this process, including vedolizumab, natalizumab, etrolizumab, PF-547659, alicaforsen, efalizumab, and emerging members of this class.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Mahmoud H. Mosli
    • 1
    • 3
    • 2
  • Jesus Rivera-Nieves
    • 4
  • Brian G. Feagan
    • 1
    • 2
  1. 1.Department of MedicineUniversity of Western OntarioLondonCanada
  2. 2.Robarts Clinical Trials Inc, Robarts Research InstituteUniversity of Western OntarioLondonCanada
  3. 3.Department of MedicineKing Abdulaziz UniversityJeddahSaudi Arabia
  4. 4.Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease CenterUniversity of CaliforniaSan DiegoUSA